Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484415 | 0.87 | NPC1 (0.62) | RAB9ANPC1SMN1; SMN2CYP2C9NR4A2 | |
| SCHEMBL2483734 | 0.85 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2TP53CYP2C9 | |
| SCHEMBL2483148 | 0.84 | NPC1 (0.62) | RAB9ANPC1SMN1; SMN2CYP2C9NR4A2 | |
| SCHEMBL3365520 | 0.82 | NPC1 (0.65) | RAB9ANPC1SMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL3368461 | 0.80 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL2485532 | 0.79 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2CYP2C9NR4A2 | |
| SCHEMBL3365483 | 0.78 | NPC1 (0.67) | RAB9ANPC1SMN1; SMN2CYP2C9NR4A2 | |
| SCHEMBL3367654 | 0.77 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2CYP2C9NR4A2 | |
| SCHEMBL2487512 | 0.77 | NPC1 (0.62) | RAB9ANPC1SMN1; SMN2CYP2C9NR4A2 | |
| SCHEMBL3371374 | 0.77 | NPC1 (0.62) | RAB9ANPC1SMN1; SMN2CYP2C9NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225245-B1 | N-phenyl-imidazo(1,2-a)pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-10-19 | — | — | EP | claimed |
| US-20100317620-A1 | N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| EP-2225245-B1 | N-phenyl-imidazo(1,2-a)pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-10-19 | — | — | EP | disclosed |
| US-20100317620-A1 | N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317620-A1 | N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF | GLS, REN, XDH | RAB9A 1438/4885NPC1 595/4885SMN1; SMN2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.